Karyopharm Therapeutics Inc. (KPTI): Price and Financial Metrics


Karyopharm Therapeutics Inc. (KPTI)

Today's Latest Price: $14.84 USD

0.14 (0.95%)

Updated Sep 25 4:00pm

Add KPTI to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 233 in Medical - Pharmaceuticals

See all "A" rated Strong Buy stocks

KPTI Stock Summary

  • With a price/sales ratio of 13.03, Karyopharm Therapeutics Inc has a higher such ratio than 89.56% of stocks in our set.
  • Revenue growth over the past 12 months for Karyopharm Therapeutics Inc comes in at 721.33%, a number that bests 98.92% of the US stocks we're tracking.
  • Shareholder yield, a measure of how much is returned to shareholders via dividends and share repurchases, for KPTI comes in at -20.09% -- higher than that of just 18.23% of stocks in our set.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Karyopharm Therapeutics Inc are RTRX, VERU, ATNX, BLDP, and PFNX.
  • KPTI's SEC filings can be seen here. And to visit Karyopharm Therapeutics Inc's official web site, go to www.karyopharm.com.
KPTI Daily Price Range
KPTI 52-Week Price Range

KPTI Stock Price Chart Technical Analysis Charts


KPTI Price/Volume Stats

Current price $14.84 52-week high $29.61
Prev. close $14.70 52-week low $8.91
Day low $14.40 Volume 2,115,291
Day high $15.17 Avg. volume 1,664,523
50-day MA $15.78 Dividend yield N/A
200-day MA $18.18 Market Cap 1.09B

Karyopharm Therapeutics Inc. (KPTI) Company Bio


Karyopharm Therapeutics is a clinical-stage pharmaceutical company focused on the discovery and development of drugs directed against nuclear transport targets for the treatment of cancer and other major diseases. The company was founded in 2008 and is based in in Newton, Massachusetts.


KPTI Latest News Stream


Event/Time News Detail
Loading, please wait...

KPTI Latest Social Stream


Loading social stream, please wait...

View Full KPTI Social Stream

Latest KPTI News From Around the Web

Below are the latest news stories about Karyopharm Therapeutics Inc that investors may wish to consider to help them evaluate KPTI as an investment opportunity.

Karyopharm Therapeutics Inc (KPTI) Investor Presentation - Slideshow

The following slide deck was published by Karyopharm Therapeutics Inc. in conjunction with this event....

SA Transcripts on Seeking Alpha | September 15, 2020

How Should Investors React To Karyopharm Therapeutics' (NASDAQ:KPTI) CEO Pay?

Michael Kauffman became the CEO of Karyopharm Therapeutics Inc. (NASDAQ:KPTI) in 2011, and we think it's a good time...

Yahoo | September 14, 2020

Karyopharm Announces XPOVIO® (selinexor) Clinical Data to be Presented at European Society for Medical Oncology Virtual Congress 2020

Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that four abstracts have been selected for poster presentation at the European Society for Medical Oncology (ESMO) Virtual Congress 2020 taking place from September 19-21. Three abstracts from investigator-sponsored studies will feature clinical data related to XPOVIO (selinexor), the Company's first in class, oral Selective Inhibitor of Nuclear Export (SINE) compound, including: (i) combination data with pembrolizumab for the treatment of melanoma, (ii) combination data with carboplatin and paclitaxel for the treatment of advanced or metastatic solid tumors, and (iii) combination data with topotecan for the treatment of advanced or metastatic sol...

Yahoo | September 14, 2020

Implied Volatility Surging for Karyopharm Therapeutics (KPTI) Stock Options

Investors need to pay close attention to Karyopharm Therapeutics (KPTI) stock based on the movements in the options market lately.

Yahoo | September 11, 2020

Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Karyopharm Therapeutics Inc. (Nasdaq: KPTI), an innovation-driven pharmaceutical company, today announced that the Compensation Committee of Karyopharm's Board of Directors granted stock options to purchase an aggregate of 29,600 shares of Karyopharm's common stock to seven newly-hired employees, with a grant date of August 31, 2020. The stock options were granted as inducements material to the new employees entering into employment with Karyopharm in accordance with Nasdaq Listing Rule 5635(c)(4).

Yahoo | September 1, 2020

Read More 'KPTI' Stories Here

KPTI Price Returns

1-mo 4.95%
3-mo -19.44%
6-mo -25.87%
1-year 51.12%
3-year 35.15%
5-year 30.63%
YTD -22.59%
2019 104.59%
2018 -2.40%
2017 2.13%
2016 -29.06%
2015 -64.60%

Continue Researching KPTI

Want to see what other sources are saying about Karyopharm Therapeutics Inc's financials and stock price? Try the links below:

Karyopharm Therapeutics Inc (KPTI) Stock Price | Nasdaq
Karyopharm Therapeutics Inc (KPTI) Stock Quote, History and News - Yahoo Finance
Karyopharm Therapeutics Inc (KPTI) Stock Price and Basic Information | MarketWatch


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.6893 seconds.